USA - NASDAQ:ATHA - US04746L1044 - Common Stock
ChartMill assigns a Buy % Consensus number of 46% to ATHA. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-09-19 | Mizuho | Downgrade | Outperform -> Neutral |
| 2024-09-04 | BTIG | Downgrade | Buy -> Neutral |
| 2024-09-04 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2024-08-19 | Rodman & Renshaw | Initiate | Buy |
| 2024-06-20 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-05-16 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-08-11 | JMP Securities | Maintains | Outperform -> Outperform |
| 2023-05-15 | Mizuho | Maintains | Buy -> Buy |
| 2023-03-30 | BTIG | Maintains | Buy |
| 2023-03-24 | JMP Securities | Reiterate | Market Outperform |
| 2022-07-07 | Mizuho | Initiate | Buy |
| 2022-06-23 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2022-06-23 | Stifel | Downgrade | Buy -> Hold |
| 2022-06-23 | Jefferies | Downgrade | Buy -> Hold |
| 2022-05-10 | BTIG | Initiate | Buy |
| 2022-04-21 | Berenberg | Initiate | Buy |
| 2021-12-15 | Goldman Sachs | Initiate | Neutral |
The consensus rating for ATHIRA PHARMA INC (ATHA) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.